Resveratrol Attenuates Both Small Bowel and Liver Changes in Obstructive Jaundice

Abstract

Background: It is well known that mucosal changes and alterations in liver function occur in the experimental obstructive jaundice model. Aims: We aimed to evaluate the effect of resveratrol on obstructive jaundice-induced changes in the small bowel mucosa and liver using ischaemia-modified albumin as a marker of oxidative damage. Study Design: Animal experimentation. Methods: The study used a rodent experimental model of obstructive jaundice, including a sham group (1), a control group (2), and a study group (3). Wistar albino rats were used. Jaundice was produced by ligation of the bile duct in Groups 2 and 3. In Group 3, resveratrol was administered intraperitoneally for 14 days. Results: In terms of the structure and the size of the mucosal villi, significant thickening and blunting were detected in Group 2 compared with Group 1. These changes were significantly less noticeable in Group 3 compared with Group 2. Levels of ischaemia-modified albumin were significantly higher in Group 2 compared with those in Group 1, and they were significantly decreased in Group 3 compared with Group 2. Conclusion: Resveratrol administration to obstructive jaundiced rats reduced the organic effects of obstructive jaundice on small bowel mucosa and liver oxidative stress. We believe that this reduction might attenuate bacterial translocation and systemic effects of secreted cytokines. (Balkan Med J 2014;31:95-99).

Keywords

• Experimental, ischemia modified albumin, jaundice, obstructive, resveratrol

Resveratrol Attenuates Both Small Bowel and Liver Changes in Obstructive Jaundice

Öz

References

1. Gonzalez-Correa JA, De La Cruz JP, Martin-Aurioles E, Lopez-Egea MA, Ortiz P, Sanchez de la Cuesta F. Effects of S-adenosyl-L-methio- nine on hepatic and renal oxidative stress in an experimental model of acute biliary obstruction in rats. Hepatology 1997;26:121-7. [CrossRef]
2. Singh S, Shackleton G, Ah-Sing E, Chakraborty J, Bailey ME. An- tioxidant defenses in the bile duct-ligated rat. Gastroenterology 1992;103:1625-9.
3. Sokol RJ, Devereaux M, Khandwala RA. Effect of dietary lipid and vita- min E on mitochondrial lipid peroxidation and hepatic injury in the bile duct-ligated rat. J Lipid Res 1991;32:1349-57.
4. Cantürk NZ, Canturk Z, Utkan NZ, Yenisey C, Ozbilim G, Yildirir C, et al. Cytoprotective effects of alpha tocopherol against liver injury induced by extrahepatic biliary obstruction. East Afr Med J 1998;75:77-80.
5. Yamauchim N, Kuriyama H, Watanabe N, Neda H, Maeda M, Niitsa Y. Intracelluler hydroxyl radical production induced by recombinant hu- man tumor necrosis factor and its implication in the killing of tumor cells in vitro. Cancer Res 1989;49:1671-5.
6. Galicia-Moreno M, Favari L, Muriel P. Antifibrotic and antioxidant ef- fects of n-acetylcysteine in an experimental cholestatic model. Eur J Gastroenterol Hepatol 2012;24:179-85. [CrossRef]
7. Krahenbuhl S, Talos C, Lauterburg BH, Reichen J. Reduced antioxida- tive capacity in liver mitochondria from bile duct ligated rats. Hepatol- ogy 1995;22:607-12. [CrossRef]
8. Sgambato A, Ardito R, Faraglia B, Boninsegna A, Wolf FI, Cittadini A. Resveratrol, a natural phenolic compound, inhibits cell proliferation and prevents oxidative DNA damage. Mutat Res 2001;496:171-80. [CrossRef]

9. Burkitt MJ, Duncan J. Effects of trans-resveratrol on copper-dependent hydroxyl-radical formation and DNA damage: evidence for hydroxyl- radical scavenging and a novel, glutathione-sparing mechanism of ac- tion. Arch Biochem Biophys 2000;381:253-63. [CrossRef]
10. Chen CY, Tsai WL, Lin PJ, Shiesh SC. The value of serum ischemia- modified albumin for assessing liver function in patients with chronic liver disease. Clin Chem Lab Med 2011;49:1817-21. [CrossRef]
11. Bar-Or D, Lau E, Winkler JV. A novel assay for cobalt-albumin bind- ing and its potential as a marker for myocardial ischemia-a preliminary report. J Emerg Med 2000;19:311-5. [CrossRef]
12. Sharma R, Gaze DC, Pellerin D, Mehta RL, Gregson H, Streather CP, et al. Evaluation of ischaemia-modified albumin as a marker of myocardial isch- aemia in end-stage renal disease. Clin Sci (Lond) 2007;113:25-32. [CrossRef]
13. Chan B, Dodsworth N, Woodrow J, Tucker A, Haris R. Site-specific N-terminal auto-degradation of human serum albumın. Eur J Biochem 1995;227:524-8. [CrossRef]
14. Parks RW, Stuart Cameron CH, Gannon CD, Pope C, Diamond T, Row- lands BJ. Changes in gastrointestinal morphology associated with ob- structive jaundice. Pathol 2000;192:526-32. [CrossRef]
15. Assimakopoulos SF, Thomopoulos KC, Patsoukis N, Georgiou CD, Scopa CD, Nikolopoulou VN, et al. Evidence for intestinal oxidative stress in pa- tients with obstructive jaundice. Eur J Clin Invest 2006;36:181-7. [CrossRef]
16. Kuzu MA, Kale IT, Cöl C, Tekeli A, Tanik A, Köksoy C. Obstructive jaundice promotes bacterial translocation in humans. Hepatogastroen- terology 1999;46:2159-64.
17. Fouts DE, Torralba M, Nelson KE, Brenner DA, Schnabl B. Bacterial translocation and changes in the intestinal microbiome in mouse models of liver disease. J Hepatol 2012;56:1283-92. [CrossRef]
18. Assimakopoulos SF, Tsamandas AC, Louvros E, Vagianos CE, Nikolo- poulou VN, Thomopoulos KC, et al. Intestinal epithelial cell prolifera- tion, apoptosis and expression of tight junction proteins in patients with obstructive jaundice. Eur J Clin Invest 2011;41:117-25. [CrossRef]
19. Bemelmans MH, Gouma DJ, Greve JW, Buurman WA. Cytokines tumor necrosis factor and interleukin-6 in experimental biliary obstruction in mice. Hepatology 1992;15:1132-6. [CrossRef]
20. Wang P, Gong G, Wei Z, Li Y. Ethyl pyruvate prevents intestinal in- flammatory response and oxidative stress in a rat model of extrahepatic cholestasis. J Surg Res 2010;160:228-35. [CrossRef]
21. Liu TZ, Lee KT, Chern CL, Cheng JT, Stern A, Tsai LY. Free radical- triggered hepatic injury of experimental obstructive jaundice of rats in- volves overproduction of proinflamatory cytokines and enhanced activa- tion of nuclear factor kappaB. Ann Clin Lab Sci 2001;31:383-90.
22. Hennet T, Richter C, Peterhans E. Tumour necrosis factor-alpha induces superoxide anion generation in mithocondria of L929 cells. Biochem J 1993;289:587-92.
23. Pastor A, Collado PS, Almar M, Gonzalez-Gallego J. Antioxidant en- zyme status in biliary obstructed rats:effects of N-acetylcysteine. J Hep- atol 1997;27:363-70. [CrossRef]
24. Ara C, Kirimlioglu H, Karabulut AB, Coban S, Ay S, Harputluoglu M, et al. Protective effect of resveratrol against oxidative stress in cholestasis. J Surg Res 2005;127:112-7. [CrossRef]
25. Kirimlioglu V, Ara C, Yilmaz M, Ozgor D, Isik B, Sogutlu G, et al. Resveratrol, a red wine constituent polyphenol, protects gastric tissue against the oxidative stress in cholestatic rats. Dig Dis Sci 2006;51:298- 302. [CrossRef]
26. Rubiolo JA, Mithieux G, Vega FV. Resveratrol protects primary rat he- patocytes against oxidative stress damage: activation of the Nrf2 tran- scription factor and augmented activities of antioxidant enzymes. Eur J Pharmacol 2008;591:66-72. [CrossRef]
27. Stillman AE, Giordano GF. Spur cell anemia associated with extrahe- patic biliary tract obstruction. Am J Gastroenterol 1983;78:589-92.
28. Sinha MK, Roy D, Gaze DC, Collinson PO, Kaski JC. Role of “isch- emia modified albumin,” a new biochemical marker of myocardial isch- aemia, in the early diagnosis of acute coronary syndromes. Emerg Med J 2004;21:29-34. [CrossRef]
29. Valle Gottlieb MG, da Cruz IB, Duarte MM, Moresco RN, Wiehe M, Schwanke CH, et al. Associations among metabolic syndrome, isch- emia, inflammatory, oxidatives, and lipids biomarkers. J Clin Endocri- nol Metab 2010;95:586-91. [CrossRef]
30. Mentese A, Turkmen S, Karaguzel E, Karaca Y, Tatli O, Sumer AU, et al. The predictive value of ischemia-modified albumin in long-term re- sults of ischemia-reperfusion injury in an experimental testicular torsion model. Urology 2012;80:689-94. [CrossRef]